NYSEHealth CareMedical Care FacilitiesSnapshot 2026-07-23
Reading USPH? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on organic growth and strategic acquisitions. The current thesis state is intact, supported by strong recent financial performance, but there are elevated risks due to industry peers' recent earnings misses.
The valuation is considered expensive compared to peers, with a premium of 1.32. The market seems to have high expectations, as indicated by a 0.3 expectations gap, suggesting that any negative news could impact sentiment.
Fundamentals are likely to remain strong in the near term, supported by revenue growth and ongoing acquisitions. However, there is a risk of missing earnings again, as the company has a history of consecutive misses and industry peers have also struggled recently.
The thesis hinges on the company's ability to maintain guidance and the performance of sector bellwethers like HCA, THC, and DVA. Positive earnings from these peers could support USPH, while negative results could lead to downward pressure.
Overall, USPH is navigating a complex environment with strong growth initiatives but faces risks from sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings report showed a significant miss. This has raised concerns about future performance. The company's fundamentals are still intact, but the earnings miss is a threat.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: The earnings report will show how revenue is growing and how well the company runs.
Confirms one read:The earnings report shows better revenue and margin numbers than Q1 2026.
Confirms the other:Earnings report shows declining revenue or margins compared to Q1 2026.
Why it matters: More patient visits show strong demand. This helps the company make more money.
Confirms:Average daily visits per clinic exceed 32.0 in Q2 2026.
Disproves:Average daily visits per clinic fall below 31.0 in Q2 2026.
Why it matters: Lower revenue growth might mean less demand or problems in execution. This raises worries about the company's growth.
Confirms:Q2 2026 total revenue growth below 7.5% year over year.
Disproves:Q2 2026 total revenue growth above 7.5% year over year.
Why it matters: This purchase could increase revenue. It may also help USPH grow its market.
Confirms:The purchase adds at least $12 million in yearly revenue and 112,000 visits.
Disproves:The acquisition fails to generate expected revenue or patient visits in the first six months.
Why it matters: Improving operating income is crucial for long-term growth. Weak results could raise concerns.
Confirms:Operating income is better in Q2 results than in earlier quarters.
Disproves:Operating income stays the same or drops in Q2 results.
Why it matters: Updates on clinic expansion are key to revenue growth. Delays could hinder overall performance.
Confirms:Management shares news about new clinics or expansion plans in Q2 earnings.
Disproves:Management did not update on clinic expansion in Q2 earnings.
Why it matters: These partnerships will likely increase revenue and EBITDA in the next few quarters.
Confirms:Revenue from hospital partnerships contributes at least $6 million to USPH in Q2 2026.
Disproves:Hospital partnerships bring in less than $3 million in Q2 2026.
Why it matters: Good use of tech can make things run better. It can also help patients.
Confirms:Using AI for paperwork shows clear gains in speed.
Disproves:No clear gains in speed or output from tech projects.
Why it matters: Working with hospitals could increase patient volume. This may lead to more revenue.
Confirms:Management says they have started hospital partnerships. These partnerships help them make more money.
Disproves:No updates on hospital partnerships or delays in starting them.
Why it matters: A successful rollout could bring more patients and money. This would support management's growth plan. Delays might show risks in execution.
Confirms:Completion of the NYU partnership rollout by the end of Q3 2026.
Disproves:Significant delays in the NYU partnership rollout beyond Q3 2026.
Why it matters: A drop in adjusted EBITDA might show problems in operations or higher costs. This raises worries about making money.
Confirms:In Q2 2026, adjusted EBITDA is less than $25 million.
Disproves:In Q2 2026, adjusted EBITDA is more than $25 million.
Why it matters: New acquisitions could signal continued growth and expansion. Lack of new deals may indicate a slowdown in growth strategy.
Confirms:More acquisitions will be announced in 2026.
Disproves:No new acquisitions announced by the end of 2026.
